Servier Pharmaceuticals
Independent global pharmaceutical group with a foundation governance model. Focus areas include oncology, cardiometabolism, neuroscience and immuno-inflammatory diseases. Emphasizes precision medicine and biomarker-driven development, translational research, multinational clinical development, manufacturing and bioproduction capacity, and external partnerships to expand R&D and diagnostics capabilities. Operates research and development centers in Europe and the U.S. and reports sustained R&D investment.
Industries
Nr. of Employees
large (251-1000)
Servier Pharmaceuticals
Patents
Substituted pyridazinones for use in the treatment of neuromuscular diseases
US-12758551-B2
View DetailsCocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
US-12679820-B2
View Details
Substituted pyridazinones for use in the treatment of neuromuscular diseases
US-12758551-B2
View DetailsCocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
US-12679820-B2
View DetailsProducts
Oral small-molecule IDH1 inhibitor (targeted cancer therapy)
Orally administered small-molecule inhibitor developed to target cancers driven by IDH1 mutations; used across hematologic and solid tumor development programs and regulatory submissions.
Oral small-molecule IDH1 inhibitor (targeted cancer therapy)
Orally administered small-molecule inhibitor developed to target cancers driven by IDH1 mutations; used across hematologic and solid tumor development programs and regulatory submissions.
Services
End-to-end clinical development support from early-phase proof-of-concept through pivotal Phase 3 trials, including trial design, operational execution, site activation and regulatory support.
Collaborative development and clinical validation of PCR-based companion diagnostic assays for mutation detection, with support for analytical validation and regulatory filings.
Product launch planning, market access strategy and territory licensing to support distribution of specialty and oncology medicines.
End-to-end clinical development support from early-phase proof-of-concept through pivotal Phase 3 trials, including trial design, operational execution, site activation and regulatory support.
Collaborative development and clinical validation of PCR-based companion diagnostic assays for mutation detection, with support for analytical validation and regulatory filings.
Product launch planning, market access strategy and territory licensing to support distribution of specialty and oncology medicines.
Expertise Areas
- Oncology drug development
- Precision medicine and biomarker-driven development
- Clinical trial management (Phase I–III and pivotal trials)
- Companion diagnostic development and clinical validation
Key Technologies
- Small-molecule targeted inhibitor development
- IDH1/IDH2-targeted therapeutic development
- Real-time PCR assays for companion diagnostics
- Longitudinal DNA sequencing for clonal analysis
News & Updates
Enrollment and initiation updates for pivotal Phase 3 studies evaluating an oral IDH1 inhibitor in IDH1‑mutated chondrosarcoma and myelodysplastic syndromes.
U.S. FDA accepted a supplemental submission and granted Priority Review for an IDH1-targeted oral therapy in a relapsed or refractory myelodysplastic syndromes indication.
Interim analysis showed statistically significant improvement in progression-free survival and time to next intervention for an IDH-targeted glioma trial.
Pivotal trial data reported that a combination regimen achieved a statistically significant improvement in overall survival versus comparator in refractory metastatic colorectal cancer.
Presentation of real-world evidence comparing targeted therapy regimens and reporting treatment patterns and outcomes at a major hematology meeting.
Phase 1 monotherapy data showed durable remissions and transfusion independence rates supporting regulatory submissions.
Enrollment and initiation updates for pivotal Phase 3 studies evaluating an oral IDH1 inhibitor in IDH1‑mutated chondrosarcoma and myelodysplastic syndromes.
U.S. FDA accepted a supplemental submission and granted Priority Review for an IDH1-targeted oral therapy in a relapsed or refractory myelodysplastic syndromes indication.
Interim analysis showed statistically significant improvement in progression-free survival and time to next intervention for an IDH-targeted glioma trial.
Pivotal trial data reported that a combination regimen achieved a statistically significant improvement in overall survival versus comparator in refractory metastatic colorectal cancer.
Presentation of real-world evidence comparing targeted therapy regimens and reporting treatment patterns and outcomes at a major hematology meeting.
Phase 1 monotherapy data showed durable remissions and transfusion independence rates supporting regulatory submissions.